Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAZ BABER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1740365808
CMS profile
169404
Location
NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$25.10

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $25.10 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
LivaNova USA, Inc. $25.10 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAZ BABER

NPI 1740365808 · CMS profile ID 169404

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RIAZ BABER, NPI 1740365808, CMS profile ID 169404, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740365808?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $25.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $25.1006/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844255537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.48 1
PY2021 $25.10 1
PY2022 $90.37 4
PY2023 $52.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $341,122.24 185
PY2024 Principal investigator $389,598.32 164
PY2023 Recipient $20,894.00 17
PY2023 Principal investigator $262,289.24 63
PY2022 Recipient $8,539.60 3
PY2022 Principal investigator $221,491.86 60
PY2021 Recipient $40,104.00 15
PY2021 Principal investigator $235,417.23 45
PY2020 Principal investigator $547,839.81 74
PY2019 Recipient $1,141.05 5
PY2019 Principal investigator $378,637.76 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

164 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,975.00 12/30/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995831
Principal investigator 1 PFIZER INC. $1,200.00 12/19/2024 Non-covered Recipient Entity
Amr Baber Research INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130952391
Principal investigator 1 Janssen Research & Development, LLC $8,767.00 12/18/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995839
Principal investigator 1 Janssen Research & Development, LLC $425.00 12/11/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962451
Principal investigator 1 Janssen Research & Development, LLC $2,521.13 12/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995847
Principal investigator 1 LivaNova USA, Inc. $170.00 12/05/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458223
Principal investigator 1 LivaNova USA, Inc. $85.00 11/19/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458317
Principal investigator 1 Janssen Research & Development, LLC $1,284.00 11/13/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962455
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,400.00 11/11/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138422672
Principal investigator 1 Janssen Research & Development, LLC $3,300.00 11/06/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962469
Principal investigator 1 LivaNova USA, Inc. $266.29 10/30/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455044
Principal investigator 1 PFIZER INC. $652.50 10/29/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130974377
Principal investigator 1 Janssen Research & Development, LLC $3,420.00 10/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995845
Principal investigator 1 LivaNova USA, Inc. $85.00 10/22/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458377
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,400.00 10/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138422288
Principal investigator 1 ACADIA Pharmaceuticals Inc $22,030.14 10/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138422290
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,332.04 10/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138422326
Principal investigator 1 ACADIA Pharmaceuticals Inc $27.81 10/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138422328
Principal investigator 1 Janssen Research & Development, LLC $173.61 10/10/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995849
Principal investigator 1 Janssen Research & Development, LLC $6,350.00 10/09/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962443
Principal investigator 1 Janssen Research & Development, LLC $9,678.00 10/07/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962439
Principal investigator 1 Janssen Research & Development, LLC $21,070.00 10/07/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995843
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/04/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995841
Principal investigator 1 Janssen Research & Development, LLC $41.03 10/04/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995851
Principal investigator 1 Janssen Research & Development, LLC $21.75 10/04/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995855
Principal investigator 1 PFIZER INC. $150.00 10/04/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130974436
Principal investigator 1 PFIZER INC. $1,219.73 10/04/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130974441
Principal investigator 1 LivaNova USA, Inc. $1,280.00 10/03/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1139458105
Principal investigator 1 LivaNova USA, Inc. $85.00 10/03/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458471
Principal investigator 1 Janssen Research & Development, LLC $256.00 10/02/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962471
Principal investigator 1 LivaNova USA, Inc. $266.29 09/20/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455042
Principal investigator 1 LivaNova USA, Inc. $266.29 09/20/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455050
Principal investigator 1 PFIZER INC. $652.50 09/19/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131020420
Principal investigator 1 PFIZER INC. $1,916.32 09/12/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131020424
Principal investigator 1 Janssen Research & Development, LLC $6,850.00 09/11/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962473
Principal investigator 1 Janssen Research & Development, LLC $41,800.00 09/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1078995835
Principal investigator 1 Neurocrine BioSciences Inc. $28.00 09/04/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150278124
Principal investigator 1 Neurocrine BioSciences Inc. $28.00 09/04/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150278126
Principal investigator 1 LivaNova USA, Inc. $1,280.00 08/20/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458029
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,136.14 08/19/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138422062
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,906.32 08/19/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138422086
Principal investigator 1 Janssen Research & Development, LLC $3,550.00 08/16/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962465
Principal investigator 1 Janssen Research & Development, LLC $11,510.00 08/15/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 1078995837
Principal investigator 1 ACADIA Pharmaceuticals Inc $497.16 08/13/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138422044
Principal investigator 1 LivaNova USA, Inc. $266.29 08/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455040
Principal investigator 1 LivaNova USA, Inc. $266.29 08/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455052
Principal investigator 1 LivaNova USA, Inc. $266.29 08/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455054
Principal investigator 1 LivaNova USA, Inc. $266.29 08/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455056
Principal investigator 1 ABBVIE INC. $1,000.00 08/08/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100735608
Principal investigator 1 LivaNova USA, Inc. $266.29 08/03/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455030
Principal investigator 1 LivaNova USA, Inc. $266.29 08/03/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455072
Principal investigator 1 LivaNova USA, Inc. $266.29 08/03/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455074
Principal investigator 1 LivaNova USA, Inc. $266.29 08/03/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455076
Principal investigator 1 Janssen Research & Development, LLC $492.00 08/02/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962437
Principal investigator 1 PFIZER INC. $10,081.37 07/25/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131036450
Principal investigator 1 Janssen Research & Development, LLC $300.00 07/24/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962447
Principal investigator 1 LivaNova USA, Inc. $820.00 07/23/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458665
Principal investigator 1 Janssen Research & Development, LLC $1,549.50 07/22/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 1078995833
Principal investigator 1 LivaNova USA, Inc. $266.29 07/12/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455038
Principal investigator 1 LivaNova USA, Inc. $266.29 07/12/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455058
Principal investigator 1 LivaNova USA, Inc. $266.29 07/12/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455060
Principal investigator 1 LivaNova USA, Inc. $266.29 07/12/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455062
Principal investigator 1 Janssen Research & Development, LLC $12,600.00 07/10/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962449
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,123.48 07/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138421920
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,100.11 07/08/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138421888
Principal investigator 1 ACADIA Pharmaceuticals Inc $98.01 07/08/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138421890
Principal investigator 1 Janssen Research & Development, LLC $300.00 06/25/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962445
Principal investigator 1 PFIZER INC. $150.00 06/20/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131061105
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,839.97 06/10/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138421501
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,417.50 06/10/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138421552
Principal investigator 1 Janssen Research & Development, LLC $11,863.00 06/07/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962467
Principal investigator 1 LivaNova USA, Inc. $266.29 06/07/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455036
Principal investigator 1 LivaNova USA, Inc. $266.29 06/07/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455064
Principal investigator 1 LivaNova USA, Inc. $266.29 06/07/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455066
Principal investigator 1 Neurocrine BioSciences Inc. $3,500.00 06/07/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270089
Principal investigator 1 Neurocrine BioSciences Inc. $3,150.00 06/07/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150270467
Principal investigator 1 Janssen Research & Development, LLC $16,400.00 05/24/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962463
Principal investigator 1 Janssen Research & Development, LLC $600.00 05/17/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962457
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,034.55 05/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138421145
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,522.75 05/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138421149
Principal investigator 1 Janssen Research & Development, LLC $8,300.00 05/08/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962453
Principal investigator 1 LivaNova USA, Inc. $266.29 05/08/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455034
Principal investigator 1 LivaNova USA, Inc. $266.29 05/08/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455068
Principal investigator 1 Neurocrine BioSciences Inc. $1,200.00 05/08/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273488
Principal investigator 1 Neurocrine BioSciences Inc. $264.00 05/08/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276185
Principal investigator 1 Neurocrine BioSciences Inc. $174.00 05/08/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276535
Principal investigator 1 Neurocrine BioSciences Inc. $144.00 05/08/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150276812
Principal investigator 1 Neurocrine BioSciences Inc. $28.00 05/08/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150278122
Principal investigator 1 Neurocrine BioSciences Inc. $19.79 05/08/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150278190
Principal investigator 1 Janssen Research & Development, LLC $256.00 05/03/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 1078995853
Principal investigator 1 LivaNova USA, Inc. $266.29 04/19/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455032
Principal investigator 1 LivaNova USA, Inc. $266.29 04/19/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455070
Principal investigator 1 PFIZER INC. $1,219.73 04/18/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131054214
Principal investigator 1 Neurocrine BioSciences Inc. $25,000.00 04/12/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150267351
Principal investigator 1 Neurocrine BioSciences Inc. $1,600.00 04/12/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150272811
Principal investigator 1 Neurocrine BioSciences Inc. $1,100.00 04/12/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273606
Principal investigator 1 Neurocrine BioSciences Inc. $1,000.00 04/12/2024 Non-covered Recipient Entity
AMR Baber Research Inc
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia No dispute reported 06/30/2026 1150273778
Principal investigator 1 Janssen Research & Development, LLC $5,250.00 04/10/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962461
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,399.98 04/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138420996
Principal investigator 1 Janssen Research & Development, LLC $600.00 04/01/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962459
Principal investigator 1 PFIZER INC. $893.47 03/27/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131051155
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,782.71 03/19/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138420880
Principal investigator 1 PFIZER INC. $6,574.96 03/14/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131052491
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 03/13/2024 Non-covered Recipient Entity
Amr-Baber Rsrch Inc.
67953964MDD3004 No dispute reported 06/30/2026 1078962441
Principal investigator 1 LivaNova USA, Inc. $2,365.00 03/12/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139457614
Principal investigator 1 LivaNova USA, Inc. $2,365.00 03/12/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139457966
Principal investigator 1 LivaNova USA, Inc. $85.00 02/20/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139457922
Principal investigator 1 LivaNova USA, Inc. $85.00 02/20/2024 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1139458875
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455028
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455078
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455080
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455082
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455084
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455086
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455252
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455254
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455256
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455258
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455260
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455262
Principal investigator 1 LivaNova USA, Inc. $266.29 02/16/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455264
Principal investigator 1 LivaNova USA, Inc. $225.00 01/31/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455046
Principal investigator 1 LivaNova USA, Inc. $1,914.30 01/31/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
LivaNova UNCOVER No dispute reported 06/30/2026 1139455048
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,158.19 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1138420776
Principal investigator 1 LivaNova USA, Inc. $1,124.55 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454914
Principal investigator 1 LivaNova USA, Inc. $750.60 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454916
Principal investigator 1 LivaNova USA, Inc. $750.60 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454918
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454920
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454922
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454924
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454926
Principal investigator 1 LivaNova USA, Inc. $1,124.55 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454928
Principal investigator 1 LivaNova USA, Inc. $1,124.55 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454930
Principal investigator 1 LivaNova USA, Inc. $1,210.95 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454932
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454934
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454936
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454938
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454940
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454942
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454944
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454946
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454948
Principal investigator 1 LivaNova USA, Inc. $105.30 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454950
Principal investigator 1 LivaNova USA, Inc. $135.00 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454952
Principal investigator 1 LivaNova USA, Inc. $1,228.50 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454954
Principal investigator 1 LivaNova USA, Inc. $74.25 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454956
Principal investigator 1 LivaNova USA, Inc. $1,431.00 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454958
Principal investigator 1 LivaNova USA, Inc. $1,431.00 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454960
Principal investigator 1 LivaNova USA, Inc. $135.00 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454962
Principal investigator 1 LivaNova USA, Inc. $135.00 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454964
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454966
Principal investigator 1 LivaNova USA, Inc. $792.45 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454968
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454970
Principal investigator 1 LivaNova USA, Inc. $792.45 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454972
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454974
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454976
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454978
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454980
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454982
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454984
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454986
Principal investigator 1 LivaNova USA, Inc. $687.15 01/23/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
RECOVER No dispute reported 06/30/2026 1139454988
Principal investigator 1 PFIZER INC. $1,219.73 01/18/2024 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131049706
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,154.44 01/09/2024 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1138420730